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Abstract Brain tumors typically arise sporadically and do not affect several family members
simultaneously. In the present study, we describe clinical and genetic data from two pa-
tients, a mother and her daughter, with familial brain tumors. Exome sequencing revealed
a germline missense mutation in the TP53 and ATRX genes in both cases, and a somatic
copy-neutral loss of heterozygosity (LOH) in TP53 in both atypical teratoid/rhabdoid tumor
(AT/RT) and astrocytoma tumors. ATRXmutation was associated with the loss of ATRX pro-
tein expression. In the astrocytoma case, R132Cmissense mutation was found in the known
hotspot site in isocitrate dehydrogenase 1 (IDH1) and LOHwas detected in TP53. Themoth-
er carried few other somatic alterations, suggesting that the IDH1 mutation and LOH in
TP53 were sufficient to drive tumor development. The genome in the AT/RT tumor was
atypically aneuploid: Most chromosomes had experienced copy-neutral LOH or whole-
chromosome gains. Only Chromosome 18 had normal diploid status. INI1/hSNF5/
SMARCB1 was homozygously deleted in the AT/RT tumor. This report provides further in-
formation about tumor development in a predisposed genetic background and describes
two special Li–Fraumeni cases with a familial brain tumor.
[Supplemental material is available for this article.]
INTRODUCTION
An atypical teratoid/rhabdoid tumor (AT/RT) is a highly malignant embryonal tumor of the
brain occurringmost often in infants. Regardless of intensive therapy, the outcome of the pa-
tients remains poor: the 5-yr overall survival rate is ∼30% (Fischer-Valuck et al. 2017). A mu-
tation or deletion in the INI1/hSNF5/SMARCB1 gene occurs in the majority of AT/RT tumors,
and this genetic alteration is the key finding in the diagnostic procedure (Louis et al. 2016).
Recently, Johann et al. (2016) reported the existence of three epigenetic AT/RT subgroups.
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In this study, whole-genome DNA and RNA sequencing did not reveal any recurrent geno-
mic aberrations beyond biallelic deletion of INI1. Thus, different genetic abnormalities were
not able to explain the differences between the AT/RT subgroups (Johann et al. 2016).
Diffusely infiltrating astrocytomas are the most common primary brain tumors in adult
populations. They are subdivided into low-grade diffuse astrocytomas (Grade II), anaplastic
astrocytomas (Grade III), and glioblastomas (Grade IV). Anaplastic astrocytomas are the rar-
est type of diffusely infiltrating astrocytoma (Louis et al. 2016). The standard treatment mo-
dality for diffusely infiltrating astrocytomas is surgery combined with radiation and/or
chemotherapy, but tumors acquire resistance rapidly. Mutations in isocitrate dehydrogenase
1 (IDH1) and IDH2 are found in >95% of Grade II–III gliomas and are associated with better
patient prognosis than in IDH wild-type tumors (Louis et al. 2016). However, the 5-yr survival
rate of IDH-mutated anaplastic astrocytomas is ∼55%–60% (Yan et al. 2009; Haapasalo et al.
2014).
Most brain tumors are sporadic and occur in patients with no known predisposing germ-
line variants. Several genetic variants are known to cause predisposition to brain tumors, but
these variants also increase the risk of other tumor types, and are rare in the human popula-
tion. Such variants include hemizygous alterations of the neurofibromatosis 1 (NF1)
(Gutmann et al. 2003), TP53 (Bougeard et al. 2015), as well as alterations in multiple DNA
repair genes, such as mismatch repair (MMR) genes (Wei et al. 1997), X-ray cross-comple-
mentary genes (XRCC) (Kiuru et al. 2008), and O6-methylguanine-DNA methyltransferase
(MGMT) genes (Felini et al. 2007). Germline mutations of the TP53 tumor suppressor gene
on Chromosome 17p13.1 cause Li–Fraumeni syndrome (Malkin et al. 1990). The TP53 gene
encodes a transcription factor (p53) that normally regulates the cell cycle and prevents dam-
aged cells from dividing and forming tumors (Malkin et al. 1990). The Li–Fraumeni mutations
can be inherited, or they can be de novo mutations arising early during embryogenesis or the
development of germ cells in the parent. This syndrome has been shown to be associatedwith
malignancies in a variety of tissue types (Iavarone et al. 1992; Sidransky et al. 1992; Nichols
et al. 2001; Malkin 2011; Sorrell et al. 2013). Brain tumors, such as astrocytic tumors are pos-
sible (Guha and Malkin 2017), but there are no previous reports on AT/RT with Li–Fraumeni
syndrome. Here, we report the exome sequences and detailed clinical history from two pa-
tients from the same family that have Li–Fraumeni syndrome. An anaplastic astrocytoma
was diagnosed from the mother, whereas the child suffered from a rare AT/RT with complex
copy-number alterations, including homozygous loss of INI1/hSNF5/SMARCB1 locus.
RESULTS
Clinical Presentation and Family History
The first case is a 2-yr-old girl, born at a gestational age of 33 wk with a birth weight of 1.8 kg.
She exhibited slow motor development and left side weakness after birth and received reg-
ular physiotherapy for the first months of her life. The first symptom was asymmetrical con-
vulsion during a fever at the age of 2. Two weeks later, the girl suffered from right-sided
weakness, irritation, and tiredness in the mornings. Central nervous system (CNS) magnetic
resonance imaging (MRI) revealed a cerebral, cystic, large tumor, but there were no signs of
obstruction of the cerebrospinal fluid (CSF) flow (Fig. 1A,B). A left-sided craniotomy was per-
formed under general anesthesia, and a microneurosurgical radical resection was per-
formed. A postoperative cranial MRI (1 wk later) showed that most of the tumor was
resected, and there was a 2-cm wide residual tumor in the anterior border of the resection
cavity, which was resected. Therewere no new neurological deficiencies after the procedure.
Neuropathological diagnosis was highly malignant AT/RT. The cellular marker for prolifera-
tion MIB-1, an antibody against Ki-67 antigen, index was 20%, immunohistochemical INI1
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staining was negative (i.e., pathological) (Fig. 1C). The patient was treated with induction
chemotherapy (methotrexate, vincristine, etoposide, cyclophosphamide, and cisplatin) fol-
lowed by three cycles of high-dose chemotherapy (thiotepa, carboplatin) with autologous
stem cell transplantation. New cranial and spinal MRI was performed 3 mo after the surger-
ies, but they did not reveal any evident residual or new tumors.
Nine months after diagnosis, a control cranial MRI revealed three recurrences in the
upper medial and parasagittal region of the resection cavity (Fig. 1A). A recraniotomy
and microneurosurgical tumor resection was performed under general anesthesia
(Supplemental Fig. 1). A postoperative MRI showed a small residual tumor with contrast en-
hancement, and an immediate third tumor resection was performed. Local radiotherapy was
given 50.4/1.8 Gy after the third surgery. The patient suffered from headaches and nausea,
and two newextra-axial occipital tumors appeared amonth after radiation as seen in theMRI.
The patient received palliative care and died a little more than 1 yr after the diagnosis.
The second case (mother) was ∼30 yr old and was previously considered a healthy wom-
an. Her mother had been diagnosed with carcinoma of the uterus in her 40s. The case had
previously suffered from an episode of seizures years earlier, and valproic acid was initiated
Figure 1. (A) Timeline of the clinical courses and patient treatments. Chemotherapy: induction therapy using
HD-MTX (high-dose methotrexate), VCR (vincristine), cisplatin, cyclophosphamide, and etoposide. (B) MRI of
the primary AT/RT of the child. (L) left side, (R) right side. (C ) Histology of the primary tumor of the child (200×
magnification). Scale bar, 20 μm. (D) MRI of the primary tumor of the mother. (L) left side, (R) right side. (E)
Histology of the primary anaplastic astrocytoma of the mother (200× magnification). Scale bar, 20 μm.
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as an anticonvulsant medication. Two years later, she had another episode of symmetrical
convulsions. AnMRI of theCNS revealed a left-sided, frontal, cystic tumor, which was edemic
and compressed the left lateral ventricle, but there were no signs of obstruction of the CNS
fluid flow (Fig. 1D). Craniotomy with microneurosurgical radical resection was performed.
Histopathological diagnosis was diffusively infiltrating astrocytoma Grade III (i.e., anaplastic
astrocytoma). The tumor was weakly positive in IDH1 R132H-immunostaining (Fig. 1E) and
the MIB-1 proliferation index was 5%. The mother received postoperative radiotherapy to
tumor bed 59.4/1.8 Gy. Six control cranial MRIs during the 3-yr follow-up revealed no resid-
uals or recidives. Six years after diagnosis, the patient was asymptomatic. As the child was
diagnosed with AT/RT, genetic analyses were done because of family history. The results
showed a germline TP53 mutation in both cases, which is known to cause Li–Fraumeni
syndrome.
Predisposing Germline Variants
Exome-sequencing data were generated from blood-derived DNA samples from both pa-
tients (mother and child) to characterize additional predisposing germline mutations. As al-
ready observed with Sanger sequencing, both patients had a germline nonsynonymous
single-nucleotide variant (SNV) in the TP53 gene (Table 1; Fig. 2A; Supplemental Table 1).
It was a G>A substitution in the coding strand, leading to glycine>serine amino acid substi-
tution (exon7:c.G733A, p.G245S in the transcript NM_000546). This variant has been previ-
ously linked to Li–Fraumeni, at least in sarcoma patients (Toguchida et al. 1992), and it is one
of the most frequently reported TP53missense mutations (7.4% of all) in the COSMIC data-
base (http://cancer.sanger.ac.uk/cosmic).
Quite surprisingly, both cases carried an ATRX SNV in their germline (Table 1; Fig. 2B;
Supplemental Table 1). This was an A>G conversion in the coding strand, leading to aspar-
agine>serine conversion in the amino acid sequence (exon23:c.A5579G, p.N1860S in the
transcript NM_000489). The variant has been linked to X-linked α-thalassemia/mental retar-
dation syndrome (Gibbons et al. 1995). The allele frequency of the A>G variant is 0.011 in the
Finnish cohort in the ExACdatabase (Supplemental Table 1) (http://exac.broadinstitute.org/).
Both tumors were ATRX-negative in the immunohistochemistry analysis (Fig. 1C,E).
Somatic Alterations
Tumor samples from both mother and child were analyzed with exome sequencing to reveal
genetic alterations involved in tumor development. One freshly frozen sample was obtained
from the mother during the first surgery and two tumor samples were obtained from the
child: FFPE sample from the primary surgery and a freshly frozen sample from a relapse taken
Table 1. Variant information for ATRX and TP53 germline variants, which were present in both cases
Gene Chromosome
HGVS coding
DNA
reference
HGVS protein
reference Variant type
Predicted
effect
dbSNP/
dbVar ID Genotype ClinVar ID
ATRX Chr X:76856021 NM_000489:
exon23:
c.5579A>G
NM_000489:
exon23:
p.N1860S
(p.Asn1860Ser)
Nonsynonymous
SNV
Asn1860Ser rs45439799 Heterozygous VCV000011724.1
TP53 Chr 17:7577548 NM_000546:
exon7:
c.733G>A
NM_000546:
exon7:p.G245S
(p.Gly245Ser)
Nonsynonymous
SNV
Gly245Ser rs28934575 Heterozygous VCV000012365.2
HGVS, Human Genome Variation Society; dbSNP, the Single Nucleotide Polymorphism database; dbVar the Database of Genomic Structural Variation.
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Figure 2. Both the mother and the child carried a germline mutation in both TP53 and ATRX genes. (A) The
sequencing coverage and TP53 allele fraction information in blood and tumor samples as visualized in integra-
tive genomics viewer (IGV). The green color represents the variant allele. Copy-neutral LOHwas observed in all
the tumor samples. The sequencing coverage range is indicated in square brackets. The exon, transcript base,
and amino acid information in the major transcript (NM_000546) are marked above the figure. (Bottom) TP53
mutation is located at the DNA-binding domain. (B) The sequencing coverage and ATRX allele fraction infor-
mation in blood and tumor samples as visualized in IGV. The orange color represents the variant allele. Copy-
neutral LOH was observed in both AT/RT tumor samples. The exon, transcript base, and amino acid informa-
tion in the major transcript (NM_000489) are marked above the figure. (Bottom) ATRX mutation is located at
the SNF2N domain.
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at 9 mo after initial diagnosis. Tumor purities were very high (>90%) in the child’s tumor sam-
ples, whereas the predicted purity was <60% in the mother’s tumor sample.
The mother had an R132C somatic IDH1 mutation, which is the second most common
IDHmutation in diffuse gliomas (Supplemental Table 2; Hartmann et al. 2009). Allele fraction
for this mutation was only 0.24, suggesting also rather low (∼50%) tumor purity. Additional
missense mutations were detected in six other genes in the mother’s tumor, but none of
them have been shown to have any oncogenic role in diffuse gliomas. The proportion of
the TP53 germline variant reads was increased in the mother’s tumor sample (Fig. 2A;
Supplemental Table 1), suggesting copy-neutral loss of the wild-type variant, which is com-
monly observed in Grade II–III diffuse gliomas (Hattori et al. 2016). This was indeed the case
according to the copy-number analysis that utilized both sequence coverage and heterozy-
gous allele frequencies in the germline (Fig. 3A; Supplemental Fig. 2). In addition to loss of
heterozygosity (LOH) in TP53 and the surrounding region in 17p13, only a hemizygously de-
leted region was observed in the beginning of Chromosome X (Fig. 3A; Supplemental Fig.
2). No deletions in 1p or 19q were detected.
The daughter’s tumor exhibited biallelic loss of INI1/hSNF5/SMARCB1 on Chromosome
22 (Fig. 3A,B), supported by negative INI1 staining (Fig. 1C). Biallelic loss of INI1 is the only
known recurrent alteration in AT/RT and is used as major criteria for AT/RT diagnosis (Louis
et al. 2016). Surprisingly, the child’s tumor harbored several additional copy-number alter-
ations. Most of her tumor genome was occupied by whole-chromosome losses and/or gains
(Fig. 3A; Supplemental Fig. 2). Copy-neutral LOH was observed in Chromosomes 3–6, 8–17,
19, 22, and X with a few exceptions: In the sample taken at diagnosis, Chr 12 was tetraploid,
and there was a subclonal population of cells with tetraploid Chr 11. Furthermore, there was
a third copy gain in the end 4q in the sample taken upon relapse. Both samples showed focal
biallelic loss of INI1 locus. In addition to LOH regions, Chromosomes 1, 2, 7, 20, and 21 were
either tetraploid or there was a combination of subclonal tetraploid and triploid chromo-
some counts. In the FFPE sample taken at diagnosis, the proportion of tetraploid subclone
was ∼30% for all the other chromosomes, except Chr 11, where the tetraploid proportion
was∼20% of the tumor content. In the relapse sample, the proportion of tetraploid subclone
was significantly smaller: ∼3% of the tumor content. Surprisingly, Chr 18 was the only chro-
mosome with a normal diploid chromosome count in the child’s tumors, which clearly differs
from the typical AT/RT tumors that lack copy-number alterations outside Chr 22 (Louis et al.
2016). In addition, 13 chromosomes (Chromosomes 3, 4, 6, 8, 9, 10, 12, 13, 15, 17, 19, 22,
and X) of 17 chromosomes with LOH were maternal; only Chromosomes 5, 11, 14, and 16
with LOH were inherited from the father (Supplemental Table 1). Furthermore, the child
had 28 nonsynonymous mutations in her tumors: nine mutations were present in both tumor
specimens, one only in the primary tumor, and 18 only in the recurrent tumor (Supplemental
Table 2). None of the mutations had existing COSMIC IDs.
Our literature search revealed two genes, namely DOK3 and SH3GLB2, which were mu-
tated in bothAT/RT tumors andhavebeenpreviously linked to tumor suppression in lung and
breast cancer, respectively (Berger et al. 2010; Zhang et al. 2011). Furthermore, two putative
tumor suppressor genes,NEK4 andKLF14, weremutatedonly in the recurrent AT/RT sample.
NEK4 has been reported to regulate the entry into replicative senescence andDNA-damage-
induced cell cycle arrest in fibroblasts (Nguyen et al. 2012), whereasKLF14 inhibits KRAS sig-
naling and has demonstrated tumor suppressor activity (Tetreault et al. 2013; Fan et al. 2015).
DISCUSSION
Our results show that the mother and the child had a germline nonsynonymous SNV in the
gene TP53. In addition, they both carried an ATRX SNV in their germline. As suspected, the
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Figure 3. Somatic copy-number alterations in mother’s and child’s tumors. (A) Copy-neutral LOH was ob-
served in most chromosomes in the child’s tumor, but chromosome gains were also prevalent. In the mother,
there was a copy-neutral LOH in Chr 17p.3 and a hemizygous deletion in Chr X. In the chromosomal counts
figure for the child, A represents a genomic region inherited from themother and B a genomic region inherited
from the father. Normal chromosomal count is thus marked with AB and, for example, copy-neutral LOH in
either paternal or maternal chromosomal region is marked with AA/BB. If a tumor contains two subclones
with different counts for a genomic region, the chromosomal counts for each subclone are separated with
a + sign. (B) A region in Chr 22q11.23 was homozygously deleted in both tumor samples obtained from the
child. Genes falling within this region, including SMARCB1/hSNF5/INI1, are visualized in the figure.
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mother had a somatic IDH1mutation R132C and the daughter’s tumor exhibited biallelic loss
of INI1/hSNF5/SMARCB1.
The transcriptional regulator ATRX (α-thalassemia/mental retardation syndrome X-
linked) protein is encoded by the ATRX gene, located in Xq21.1. ATRX contains an
ATPase/helicase domain, and it belongs to the SWI/SNF family of chromatin remodeling
proteins (Gibbons et al. 2000). ATRX directly interacts with DNA as well as with several func-
tional partners, presumably by assembling with different chromatin remodeling or transcrip-
tional regulatory complexes. In addition, reduced ATRX levels induce chromosome
segregation defects (Mayes et al. 2014). Similarly, INI1 is a member of the SWI/SNF family
and plays a role as a tumor suppressor in malignant rhabdoid tumors (Versteege et al.
1998). Furthermore, alternative lengthening of telomeres (ALT) is a mechanism by which
∼10%–15% of cancer cells can extend their telomeres without the enzyme telomerase.
Loss of ATRX/DAXX function appears to be required for ALT (Amorim et al. 2016).
Approximately 10%–15% of human cancers are suspected to use the ALT pathway, including
a subset of nervous system tumors (e.g., medulloblastoma, low-grade diffuse gliomas, and
ganglioneuroblastoma) (Lovejoy et al. 2012). By lengthening the telomere, ALT contributes
to the unrestricted cell division that is a hallmark of cancer and likely makes cancer cells less
vulnerable to chemotherapy or radiation therapy. These ALT-positive tumors use recombina-
tion to sustain immortality (Dilley and Greenberg 2015). Recent findings suggest that ham-
pering ALT might be a potential new cancer treatment modality. ALT is disrupted by the
inhibition of protein kinase ATR leading to cell apoptosis (Lovejoy et al. 2012). ATRX is locat-
ed in Chromosome X, and thus one of its alleles is epigenetically silenced. Both our patients
had ATRX variants in their germline. There are discordant reports about the pathogenicity of
the detectedATRX variant in ClinVar, and the variant frequency was 1.1% in a Finnish cohort,
which also suggests a lower pathogenicity. However, this variant was associated with the loss
of ATRX protein expression in both tumors. In addition, ATRX staining was negative in the
endovascular cells in the mother and in all the cells surrounding the blood vessels in the
child, suggesting that the normal ATRX allele has been imprinted in these cells. Other germ-
line mutations that are not covered by exome sequencing might also be responsible for the
ATRX loss in the variant-containing locus. Nevertheless, our data show that ATRX loss or
defect can be present also in nonmalignant cells, which might lead to undesired outcome
after ATR inhibitor based treatments. Germline status and ATRX protein detection will be in-
formative for ATRX-mutated cases if these treatment modalities become part of the clinical
practice in the future.
The IDHmutation is frequently observed with TP53 and ATRXmutations in astrocytic tu-
mors (Cai et al. 2014). IDHmutation is widely used as a clinical tool to sort glial tumors (Louis
et al. 2016), and patients with IDHmutation have better outcomes than IDHwild-type diffuse
glioma patients (Ichimura 2012). The mother carried a somatic IDH R132C mutation in her
tumor. Antibodies raised against IDH1 R132H mutation gave a weakly positive signal in im-
munohistochemistry, which suggests cross-reactivity against R132C mutation. The mother’s
outcome remains stable after 6 yr, which is better than the average prognosis. The lack of
other oncogenic alterations is somewhat surprising, but as both TP53 and ATRX harbored
a pathogenic variant already in the germline, the IDH1 hotspot mutation might have been
enough to trigger the development of a diffuse glioma. These three genes are themost com-
monly altered genes in 1p19q nondeleted IDH-mutated diffuse gliomas, such as anaplastic
astrocytoma (Cancer Genome Atlas Research Network et al. 2015).
The complexity of copy-number changes observed in the child’s tumor cells is striking.
How could this kind of genome have arisen? Most likely there was a loss of one pair for
most chromosomes, followed by genome-wide duplication of chromosome counts. The
loss of one chromosome to generate triploid counts could have happened soon after in
Chr 2 and Chr 20, and possibly in Chr 1p. The fact that there was a combination of both
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tetraploid and hemizygously deleted diploid Chr 11 chromosome counts in the child’s first
sample (child FFPE) suggests that the observed gains and losses took place sequentially,
rather than simultaneously in all the chromosomes. The hemizygous loss of Chr 17 has gen-
erated a homozygous missense mutation in TP53, which has likely damaged the p53-depen-
dent cell cycle checkpoint mechanisms (Vaziri et al. 2003). The fact that homozygous loss in
Chr 22 has similar boundaries in both chromosomes suggests that the INI1 locus was fully
deleted before the suggested genome-wide gain in chromosome counts. It is difficult to
determine whether Chr 18 has remained diploid throughout all these genome rearrange-
ments or whether one copy of both maternal and paternal chromosomes has been deleted
after a tetraploid stage.
Li–Fraumeni is known to predispose humans to cancer but the question remains as towhy
both the mother and the child developed a brain tumor. It seems that the diffuse gliomas
need other genetic alterations, such as IDH and ATRX mutations, for their development.
Themother obtained somatic IDH1mutation, and she carried anATRXmutation in her germ-
line. In AT/RT, the literature has revealed only one recurrent genetic mutation—namely, ho-
mozygous loss of INI1, which was also observed in the tumor of the child.
To our knowledge, this is the first study to show that Li–Fraumeni syndrome with accom-
panying somatic LOH in a patient with AT/RT. This highlights the fact that even in rare brain
tumors, the anamnesis of family history is essential, and modern genetic analyses of tumors
and heredity should be performed.
METHODS
Immunohistochemical Analysis and Pathological Evaluation
The tumor samples were fixed in 4% phosphate-buffered formaldehyde and processed into
paraffin blocks. The sections were stained with hematoxylin and eosin (H&E). An experi-
enced neuropathologist evaluated the tumor samples and determined the histopathological
type and grade according to the criteria presented by theWorld Health Organization (WHO)
(Louis et al. 2007). The tumor immunostaining for IDH1 was performed using R132H point
mutation–specific mouse monoclonal antibody (Dianova GmbH) as previously described
(Mäkelä et al. 2014). ATRX and INI1 immunostainings were performed using Ventana
Benchmark GX immunoautomate (Ventana Medical Systems). DISCOVERY EZ Prep solution
(# 950-102, VentanaMedical Systems) was used for deparaffinization (72°C). Epitope retriev-
al was performed at 95°C in Cell Conditioning Solution CC1 (# 950-124), for 92min for ATRX
detection and 32min for INI1 detection. Antibody incubation duration was 60min with a rab-
bit polyclonal anti-ATRX antibody (dilution 1:500, HPA0001906, Atlas antibodies) and 28
min with a mouse monoclonal antibody anti-INI-1 (dilution 1:200, Clone: 25/BAF47,
612110, B&D Laboratories), both at 36°C. Both immunostainings were detected and visual-
ized usingOptiViewDAB IHCDetection Kit (# 760-7000, VentanaMedical Systems) together
with Optiview Amplification kit (# 760-099, Ventana Medical Systems). All the washes were
performed using Tris-based reaction buffer solution (# 950-300, Ventana Medical Systems).
Nuclei were visualized with Hematoxylin II (#790-2208, Ventana Medical Systems).
Exome Sequencing
DNAwas isolated from the blood samples using aQIAGEN isolation kit, from the frozen sam-
ples with a QIAamp DNAMini kit (QIAGEN) with RNAse treatment, and from the FFPE sam-
ple with a turXTRAC FFPE DNA kit (Covaris). Library construction and exome sequencing
were performed at Beijing Genomics Institute (BGI), Hong Kong. A SureSelect Human All
Exon V5 (target size 50 M) kit (Agilent) was used for library preparation, and samples were
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sequenced with Illumina HiSeq2000 technology. The pursued sequencing depth was 50×
for blood-derived samples and 100× for tumor samples (Supplemental Table 3).
Genome Alignment
The raw reads from the whole-exome sequencing experiment for each sample were aligned
to the human reference genome (hg19) using Bowtie2 (version 2.2.5) (Langmead and
Salzberg 2012) and converted to BAM format using SAMtools (version 0.1.19) (Li et al.
2009). Duplicate reads were marked and removed from the resulting BAM files using
SAMBLASTER (version 0.1.21) (Faust and Hall 2014).
Somatic Copy-Number Aberration Analysis and Tumor Purity Estimation
Aligned reads were counted in 1000-bp windows across the entire genome using BEDTools-
2.25.0 (Quinlan and Hall 2010). Coverage log ratios were calculated relative to a median ref-
erence derived from the two normal blood samples. GC fractions were calculated for all
1000-bp windows, and Loess regression was applied to coverage log ratios to correct for
GC content bias. After GC bias correction, samples were corrected for differences in overall
coverage using median-of-ratios normalization.
Heterozygous single-nucleotide polymorphisms (SNPs) were identified for each patient
by searching their normal blood sample for genomic sites that displayed an allele fraction
close to 50%. The alternate allele read count r was required to satisfy 0.05 ≤ BinCDF(r; n,
0.5)≤ 0.95, and the total read count had to be at least 50. The list of heterozygous SNPs
was further filtered to only include genomic sites annotated in the KAVIAR (Glusman et al.
2011) or ExAC databases (Lek et al. 2016). Polymorphic indels and SNPs within 10 bp of
indels (both somatic and germline) were discarded from the list of heterozygous SNPs tomit-
igate alignment artifacts.
Tumor purities were estimated based on the observed allele fractions for the detected
heterozygous germline SNPs located in regions with copy-neutral LOH in each tumor
sample.
Germline and Somatic Variant Calling
Variants were called using an inhouse variant calling pipeline based on SAMtools mpileup
output (Li et al. 2009). Variants were called heterozygous if, at a given locus, at least 20%
of all reads showed the alternate allele or homozygous alternate if, at a given locus, at least
80% of all reads showed the alternate allele. Annotation for both germline and somatic
variants was performed using ANNOVAR (Wang et al. 2010) in combination with custom
scripts. Variants were further annotated with impact on protein coding, Cosmic ID
(Bamford et al. 2004), and the SNP database (dbSNP) ID (Sherry et al. 2001). Furthermore,
annotations included allele frequencies reported in 1000 Genomes (The 1000 Genomes
Project Consortium 2010), the National Heart, Lung, and Blood Institute (NHLBI) Exome
Sequencing Project (ESP6500, unpublished; http://evs.gs.washington.edu/EVS/), SISu,
and ExAC (Lek et al. 2016). To select somatic variants, we discarded the variants that were
also detected in the respective germline sample. The rest of the somatic variants were man-
ually inspected to remove sequencing artifacts.
We discarded germline variants if the population frequency of alternate alleles was >0.01
in either of the three following cohorts: all five populations of 1000 Genomes (The 1000
Genomes Project Consortium 2010), the Sequencing Initiative Suomi cohort (SISu, unpub-
lished; http://www.sisuproject.fi/) that consists of exomes of 10,000 Finnish individuals,
and all seven populations of the ExAC cohort (Lek et al. 2016). In addition, we devised a
Bayesian scoring scheme that assigns each variant locus a score using the total, reference,
and alternate allele read count information. The score represents the confidence that at least
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1 (Bayes_score_1; Supplemental Table 1) or 2 (Bayes_score_2; Supplemental Table 1) of the
samples have variation (i.e., heterozygous or homozygous alternate) in a given locus. All the
germline variants with a Bayesian score of <0.9999999 or lack of allele frequency information
in all the above reference cohorts were discarded.
ADDITIONAL INFORMATION
Data Deposition and Access
The variants were submitted to ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) and can be
found under accession numbers SCV000693709–SCV000693712.
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